Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
News|Videos|July 27, 2023
Dr Kim on Improving Representation in Clinical Trials
Author(s)Edward S. Kim, MD, MBA
Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.
Advertisement
Edward S. Kim, MD, MBA, physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center, discusses the importance of improving representation in clinical trials.
Advertisement
Related to this article
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC
5